golidocitinib with PD-1 inhibitors

Phase 2Small molecule

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

golidocitinib with PD-1 inhibitors is one of 9 small molecule programs targeting Maintenance Treatment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Maintenance TreatmentRecruiting

Maintenance TreatmentPhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Maintenance Treatment

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

2 2

Libtayo

Regeneron

Phase 2

1 3

Chidamide

CChipscreen Biosciences, Ltd.

Phase 3

2 4

Zejula

GGlaxo Dba Glaxosmithkline

Phase 2

3 5

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 6

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 7

Kyprolis

VVirionyx Corporation Limited

Phase 2

1 8

Cytovene

EExela Pharma Sciences, LLC.

Preclinical

1 9

golidocitinib with PD-1 inhibitors

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Maintenance Treatment

NCT07110103

Clinical

Trials by Indication[1]

Maintenance Treatment1 trial

Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC

Recruiting·—·Phase 2·NCT07110103·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for golidocitinib with PD-1 inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — golidocitinib with PD-1 inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for golidocitinib with PD-1 inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cancer Institute and Hospital, Chinese Academy of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCancer Institute and Hospital, Chinese Academy of Medical Sciences

golidocitinib with PD-1 inhibitors

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Maintenance Treatment1 trial

References

Drug Info

Quick Facts

Related News